Trials / Completed
CompletedNCT00143481
Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women
A Multi-Center, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women With Overactive Bladder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the impact of treatment with tolterodine ER versus placebo on Urgency Urinary Incontinence in sexually active women with OAB symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tolterodine ER 4mg QD |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2006-06-01
- First posted
- 2005-09-02
- Last updated
- 2021-01-27
Locations
58 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00143481. Inclusion in this directory is not an endorsement.